Vir Biotechnology, Inc.
VIR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VIR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VIR
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing transformative therapies for infectious diseases and oncology, with a pipeline including chronic hepatitis delta and other viral programs.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 13 clinical trials · 3 catalysts for Vir Biotechnology, Inc..
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing transformative therapies for infectious diseases and oncology, with a pipeline including chronic hepatitis delta and other viral programs.
- Cash & equivalents of $287.6M as of 2026-06-30 [sec].
- Total revenue of $238.9M and net income of $80.1M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $947.5M as of 2026-06-30 [sec].
- Accumulated deficit of $1.2 billion as of 2026-02-23 [sec_mda].
- Received $315.0M from Astellas in 2024, including a $240.0M upfront payment [sec_mda · as of 2026-08-05].
What works
- Strong cash position of $287.6M as of 2026-06-30 provides runway for at least 12 months [sec].
- Recent net income of $80.1M for the period ended 2026-06-30 indicates improved financial performance [sec].
- Strategic collaboration with Sanofi and Astellas provides non-dilutive capital and development support [sec_mda · as of 2026-08-05].
- Industry-leading management team with experience in immunology, infectious diseases, and oncology [sec_mda · as of 2025-02-27].
What to weigh
- Accumulated deficit of $1.2 billion as of 2026-02-23 reflects historical losses [sec_mda].
- No approved products generating revenue; company expects to incur net losses for the foreseeable future [sec_mda · as of 2026-05-07].
- Clinical development costs and milestone payments are uncertain and may require additional capital [sec_mda · as of 2026-08-05].
- FDA revoked EUA for sotrovimab in December 2024, eliminating a prior revenue source [sec_mda · as of 2025-11-05].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2026-12-31 · Phase2_Topline · vir-5818 — Phase 2 readout for vir-5818 will provide efficacy and safety data.
- 2031-05-01 · Phase3_Topline — Phase 3 Topline: A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran — Phase 3 topline results for tobevibart + elebsiran will inform regulatory potential.
- 2031-07-01 · Phase3_Topline — Phase 3 Topline: A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran C — Additional Phase 3 topline data for tobevibart + elebsiran C will be reported.
Risks & what to watch (4)›
Key risks
- No approved products — Company does not expect significant revenue from product sales until regulatory approvals, if ever [sec_mda · as of 2026-05-07].
- Clinical development uncertainty — Costs and timelines for clinical programs are unpredictable; may need additional capital [sec_mda · as of 2026-08-05].
- Historical accumulated deficit — Accumulated deficit of $1.2 billion as of 2026-02-23 indicates long-term unprofitability [sec_mda].
- Dependence on collaborations — Success depends on collaborators' ability to develop licensed product candidates [sec_mda · as of 2026-08-05].
What to watch
- Phase 2 topline data for vir-5818 expected by 2026-12-31 [catalyst].
- Phase 3 topline data for tobevibart + elebsiran expected by 2031-05-01 [catalyst].
- Additional Phase 3 topline data for tobevibart + elebsiran C expected by 2031-07-01 [catalyst].
- Cash runway updates and potential need for additional financing [sec_mda · as of 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Vir Biotechnology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vir Biotechnology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.24 · 1% dilution
Lead: Phase 3
5 candidates
3 upcoming, next in ~123d
0 buys · 6 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
254
Total value held
$1.23B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 17,998,329 | $161.3M |
| arch venture management, llc | 12,916,663 | $115.7M |
| sb investment advisers (uk) ltd | 10,948,093 | $98.1M |
| vanguard capital management llc | 10,764,206 | $96.4M |
| vanguard portfolio management llc | 9,215,577 | $82.6M |
| state street corp | 7,141,094 | $64.0M |
| goldman sachs group inc | 3,250,227 | $29.1M |
| morgan stanley | 2,854,205 | $25.6M |
| adar1 capital management, llc | 2,744,714 | $24.6M |
| geode capital management, llc | 2,657,843 | $23.8M |
Showing top 10 of 254 institutional holders of Vir Biotechnology, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.7%
- Days to cover
- 9.0
- Shares short
- 16,117,209
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VIR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vir Biotechnology, Inc.?
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing transformative therapies for infectious diseases and oncology, with a pipeline including chronic hepatitis delta and other viral programs.
What is Vir Biotechnology, Inc.'s lead drug candidate?
Vir Biotechnology, Inc.'s most advanced tracked candidate is elebsiran (Phase 3) for Viral Hepatitis.
What is Vir Biotechnology, Inc.'s next catalyst?
Vir Biotechnology, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: vir-5818" — expected December 31, 2026.
Who is the CEO of Vir Biotechnology, Inc.?
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. is the chief executive officer of Vir Biotechnology, Inc. (VIR).
Where is Vir Biotechnology, Inc. headquartered?
Vir Biotechnology, Inc. (VIR) is headquartered in San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.